JAK2 inhibition has different therapeutic effects according to myeloproliferative neoplasm development in mice
JAK2 inhibition therapy is used to treat patients suffering from myeloproliferative neoplasms (MPN). Conflicting data on this therapy are reported possibly linked to the types of inhibitors or disease type. Therefore, we decided to compare in mice the effect of a JAK2 inhibitor, Fedratinib, in MPN m...
Main Authors: | Debeurme, Franck, Lacout, Catherine, Moratal, Claudine, Bagley, Rebecca G, Vainchenker, William, Adrian, Francisco, Villeval, Jean-Luc |
---|---|
Format: | Online |
Language: | English |
Published: |
John Wiley & Sons, Ltd
2015
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4627562/ |
Similar Items
-
Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors
by: Choong, Meng Ling, et al.
Published: (2013) -
JAK2 Inhibition: Reviewing a New Therapeutical Option in Myeloproliferative Neoplasms
by: Bellido, Mar, et al.
Published: (2012) -
Mouse models of myeloproliferative neoplasms: JAK of all grades
by: Li, Juan, et al.
Published: (2011) -
Myeloproliferative neoplasms and the JAK/STAT signaling pathway: an overview
by: de Freitas, Renata Mendes, et al.
Published: (2015) -
Co-targeting the PI3K/mTOR and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasms
by: Bartalucci, Niccolò, et al.
Published: (2013)